Roche’s megablockbuster MS candidate ocrelizumab posts promising head-to-head data
By most accounts, Roche’s ocrelizumab is likely the biggest drug in the industry’s late-stage pipeline, with peak revenue potential ranging up to a megablockbuster $7 billion or so. And today the company whet the appetite of analysts with a head-to-head comparison with Merck KGaA’s Rebif – already under assault from Tecfidera (Biogen), Gilenya (Novartis) and Aubagio (Sanofi) – that makes the new drug look even better.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.